Navigation Links
First human study confirms that immune cells can be a primary cause of bone loss in gum disease

Researchers at The Forsyth Institute have confirmed in human gingival tissue that immune cells play a destructive role in periodontal disease. Although researchers had suspected the correlation between bone loss in periodontal (gum) disease and immune cells, this is the first time that this has been confirmed in human tissue samples. With this work, Forsyth scientists and colleagues hope to determine methods for intervening and halting bone loss and thus improving the health outcomes of the estimated 80 million Americans suffering from periodontal disease.

The study, led by Toshihisa Kawai, D.D.S., Ph.D., examined whether immune response to periodontal bacteria is protective or pathogenic in the context of gum disease. Periodontal disease is an infection of the teeth, and their supporting structures, which results in soft tissue and bone destruction, leading to tooth loss. Dr. Kawai and his colleagues had found that B cells (B and T lymphocytes are immune cells) can contribute to increased periodontal bone loss coordinating with activated T-cells. Both cell types had previously been found to manifest a host immune response to the bacteria causing bone loss in animal models, by his group.

"This research validates our hypothesis that immune cells are harmful in gum disease," said Dr. Kawai. "It's a groundbreaking discovery because it truly gives a new understanding of periodontal disease, while also raising interesting questions about immune cells. We hope this work will help us save people's teeth in the future."

Research Overview
RANKL is a protein that is a major factor in the regulation of osteoclasts (cells that destroy bone). Dr. Kawai's research examined the receptor activator of NF-kB ligand, (RANKL)-mediated osteoclastogeneis, and the pivotal role it plays in inflammatory bone resorption. The aim of this study, which will be published in the September issue of the American Journal of Pathology, was to identify the cellular s ource of RANKL in the bone resorptive lesions of periodontal disease. An active periodontal lesion is characterized by the prominent infiltration of B cells and T cells, both of which are major immune lymphocytes. Specifically, the occupancy of 50-60% of such cellular infiltrates by plasma cells (ultimately, differentiated B cells) makes periodontal disease very distinct from other chronic infectious diseases. B cells are known to produce a weapon (antibody) that normally attacks bacteria and protects our body from bacterial infection. As a consequence of dense infiltration of B cells found in the gum, periodontally diseased patients mount significantly elevated antibody levels to bacteria colonizing around gum tissues. However, the fact that periodontal disease continues to progress, even though B cells produce a weapon to fight off the bacteria, raised an important and interesting question. To answer this question, Dr. Kawai's group found that RANKL expressed on the T and B cells in the patient's gingival tissues were functionally sufficiently potent to induce bone destructive cells (osteoclasts) in a laboratory culture system, in spite of the elevated presence of B and T lymphocytes. Since it has never been reported that any bacteria per se invade and resorb bone independent of osteoclast activation, RANKL expression by T cells and B cells proves to be one of the major stimuli of osteoclast precursor cells and, hence, bone loss through periodontal disease.


'"/>

Source:Forsyth Institute


Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology: